Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Aristotle Core Equity Fund Mr. Fitzpatrick | “Guardant Health contributed to performance in the second quarter following a string of positive developments, as several catalysts played out during the quarter. The...” | BULL | Q2 2026 Aug 10, 2026 | View Pitch |
Baron Health Care Fund Neal Kaufman | “Guardant is a specialty diagnostics company best known for its blood-based liquid biopsy tests used in cancer therapy selection, monitoring, and screening. Shares increased following strong first-quarter results, with revenue growing 48% year-over-year due to continued adoption of the Guardant360 cancer treatment selection test and accelerating uptake of the Shield colorectal cancer blood test. Guardant360 continues to gain share within the rapidly growing liquid biopsy market, with momentum accelerating following FDA approval of the new Guardant360 Liquid CDx assay, which should qualify for Advanced Diagnostic Laboratory Test status and meaningfully expand average selling prices. Meanwhile, Shield has the potential to drive meaningful upside as adoption continues to beat expectations. Notably, the American Cancer Society recently recommended Shield in its updated colorectal cancer screening guidelines, significantly increasing the potential for expanded commercial insurance coverage. Looking ahead, we see Guardant360, Shield, and Reveal (Guardant's cancer recurrence monitoring test) positioning the company to achieve positive free cash flow over time.” | NEUTRAL | Q2 2026 Jul 23, 2026 | View Pitch |
Alger Small Cap Focus Fund Amy Zhang | “Guardant Health is a molecular diagnostics company specializing in liquid biopsy tests for oncology applications. Unlike traditional tissue-based tests, Guardant's liquid biopsies use blood samples, enabling faster results and improved patient comfort. The company's tests include comprehensive genomic profiling, cancer diagnosis, and treatment monitoring. Shares contributed to performance after the company delivered strong fiscal third-quarter operating results and raised full-year 2025 revenue guidance, signaling stronger-than-expected momentum across Oncology, Screening, and Biopharma & Data. BSD Analysis: Guardant is a pioneer in liquid biopsy, enabling cancer detection and monitoring through blood-based genomic testing. Its strength lies in oncology, where longitudinal monitoring and treatment selection drive repeat testing. Gross margins are improving, but cash burn remains elevated as the company invests ahead of scale. Clinical validation continues to expand Guardant's relevance across cancer types. Competition is intense, but Guardant's data depth and physician adoption remain advantages. Reimbursement expansion is the key catalyst. This is a high-growth oncology diagnostics name still proving economic durability.” | BULL | Q4 2025 Jan 8, 2026 | View Pitch |
Invesco Discovery Fund Ronald Zibelli, Asutosh Shah | “Guardant Health provides blood-based diagnostic and monitoring tests for cancer treatment. During the quarter, management reported strong quarterly financial results. The stock also rallied after the release of disappointing data for a competitor's blood-based cancer test, which no longer appears to be a threat for Guardant. BSD Analysis: Guardant Health is building diagnostics infrastructure around liquid biopsy, not just selling tests. Blood-based cancer testing expands screening and monitoring precisely because it lowers friction for physicians and patients. Adoption depends on clinical utility and reimbursement, not consumer marketing, and Guardant has steadily improved on both fronts. Investors fixate on losses and ignore how scale drives gross margin inflection in diagnostics. The real value sits in longitudinal data and test integration across treatment pathways. Competition is real, but switching platforms once workflows are embedded is painful. As guidelines evolve toward less invasive testing, Guardant sits directly in the flow. This is a long-cycle healthcare platform hiding behind near-term P&L noise.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
